Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel Free NVCT Stock Alerts

Nuvectis Pharma (NVCT) Financials

Nuvectis Pharma logo
$19.63 +0.06 (+0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$19.73 +0.10 (+0.51%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Nuvectis Pharma

Annual Income Statements for Nuvectis Pharma

This table shows Nuvectis Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -19 -22 -19 -29
Consolidated Net Income / (Loss)		 -13 -19 -22 -19 -26
Net Income / (Loss) Continuing Operations		 -13 -19 -22 -19 -26
Total Pre-Tax Income 		-13 -19 -22 -19 -26
Total Operating Income		 -13 -19 -23 -20 -28
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 13 19 23 20 28
Selling, General & Admin Expense		 3.35 6.01 7.52 6.93 9.42
Research & Development Expense		 9.55 13 15 13 18
Total Other Income / (Expense), net		 0.00 0.15 0.64 0.85 1.13
Interest & Investment Income		 - - - - 1.13
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - 0.00 2.43
Basic Earnings per Share		 ($3.02) ($1.51) ($1.43) ($1.11) ($1.32)
Weighted Average Basic Shares Outstanding		 4.27M 12.66M 15.56M 17.11M 21.81M
Diluted Earnings per Share		 ($3.02) ($1.51) ($1.43) ($1.11) ($1.32)
Weighted Average Diluted Shares Outstanding		 4.27M 12.66M 15.56M 17.11M 21.81M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.75M 17.77M 23.39M 26.49M
Cash Dividends to Common per Share		 - $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Nuvectis Pharma

This table shows Nuvectis Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -9.89 -7.31 -6.05
Consolidated Net Income / (Loss)		 -5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -7.46 -7.31 -6.05
Net Income / (Loss) Continuing Operations		 -5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -7.46 -7.31 -6.05
Total Pre-Tax Income 		-5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -7.46 -7.31 -6.05
Total Operating Income		 -6.16 -6.87 -4.40 -4.64 -4.36 -6.45 -5.57 -6.60 -7.79 -7.62 -6.26
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.16 6.87 4.40 4.64 4.36 6.45 5.57 6.60 7.79 7.62 6.26
Selling, General & Admin Expense		 1.67 2.60 1.74 1.70 1.54 1.95 1.89 2.98 2.02 2.53 2.15
Research & Development Expense		 4.49 4.27 2.66 2.94 2.82 4.50 3.68 3.61 5.77 5.09 4.11
Total Other Income / (Expense), net		 0.28 0.24 0.23 0.22 0.21 0.20 0.24 0.26 0.33 0.30 0.21
Other Income / (Expense), net		 - - 0.23 0.22 - - 0.24 0.26 - - 0.21
Basic Earnings per Share		 ($0.37) ($0.41) ($0.25) ($0.26) ($0.24) ($0.36) ($0.27) ($0.30) ($0.44) ($0.31) ($0.26)
Weighted Average Basic Shares Outstanding		 16.10M 15.56M 16.56M 16.90M 17.23M 17.11M 19.94M 21.37M 22.72M 21.81M 23.41M
Diluted Earnings per Share		 ($0.37) ($0.41) ($0.25) ($0.26) ($0.24) ($0.36) ($0.27) ($0.30) ($0.44) ($0.31) ($0.26)
Weighted Average Diluted Shares Outstanding		 16.10M 15.56M 16.56M 16.90M 17.23M 17.11M 19.94M 21.37M 22.72M 21.81M 23.41M
Weighted Average Basic & Diluted Shares Outstanding		 17.33M 17.77M 18.36M 18.65M 19.32M 23.39M 23.63M 25.46M 25.61M 26.49M 26.53M

Annual Cash Flow Statements for Nuvectis Pharma

This table details how cash moves in and out of Nuvectis Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 5.74 14 -0.87 -0.59 13
Net Cash From Operating Activities		 -9.50 -14 -16 -12 -16
Net Cash From Continuing Operating Activities		 -9.50 -14 -16 -12 -16
Net Income / (Loss) Continuing Operations		 -13 -19 -22 -19 -26
Consolidated Net Income / (Loss)		 -13 -19 -22 -19 -26
Non-Cash Adjustments To Reconcile Net Income		 1.89 1.71 4.71 4.86 6.03
Changes in Operating Assets and Liabilities, net		 1.49 3.82 1.60 1.90 4.40
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 15 28 15 12 29
Net Cash From Continuing Financing Activities		 15 28 15 12 29
Repurchase of Common Equity		 0.00 - -0.17 -0.38 -2.10
Issuance of Common Equity		 0.00 32 5.29 12 31

Quarterly Cash Flow Statements for Nuvectis Pharma

This table details how cash moves in and out of Nuvectis Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.54 -2.93 0.34 -1.35 -0.95 1.36 11 -3.07 8.65 -3.81 -6.50
Net Cash From Operating Activities		 -3.24 -3.85 -4.36 -3.02 -2.40 -2.47 -4.17 -3.37 -4.49 -3.97 -6.51
Net Cash From Continuing Operating Activities		 -3.24 -3.85 -4.36 -3.02 -2.40 -2.47 -4.17 -3.37 -4.49 -3.97 -6.51
Net Income / (Loss) Continuing Operations		 -5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -7.46 -7.31 -6.05
Consolidated Net Income / (Loss)		 -5.88 -6.62 -4.17 -4.43 -4.15 -6.25 -5.33 -6.33 -7.46 -7.31 -6.05
Non-Cash Adjustments To Reconcile Net Income		 1.13 1.22 1.30 1.26 1.16 1.14 1.37 1.73 1.46 1.48 1.85
Changes in Operating Assets and Liabilities, net		 1.50 1.55 -1.48 0.15 0.59 2.64 -0.21 1.24 1.51 1.86 -2.31
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.70 0.92 4.70 1.67 1.46 3.83 16 0.30 13 0.17 0.01
Net Cash From Continuing Financing Activities		 0.70 0.92 4.70 1.67 1.46 3.83 16 0.30 13 0.17 0.01
Repurchase of Common Equity		 -0.04 0.02 -0.15 -0.06 -0.05 -0.12 -1.29 -0.32 -0.41 -0.08 0.00
Issuance of Common Equity		 1.13 0.90 4.85 1.73 1.51 3.95 17 0.61 14 0.25 0.01

Annual Balance Sheets for Nuvectis Pharma

This table presents Nuvectis Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 6.66 20 19 19 32
Total Current Assets		 5.83 20 19 19 32
Cash & Equivalents		 5.74 20 19 19 32
Other Current Assets		 0.09 0.41 0.06 0.07 0.08
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.82 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 6.66 20 19 19 32
Total Liabilities		 2.42 6.19 6.98 8.89 13
Total Current Liabilities		 2.42 6.19 6.98 8.89 13
Accounts Payable		 1.06 2.91 2.77 2.50 6.27
Accrued Expenses		 0.40 0.45 0.42 0.84 0.12
Current Employee Benefit Liabilities		 0.14 2.38 3.80 5.56 6.91
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -11 14 12 9.71 18
Total Preferred & Common Equity		 -11 14 12 9.71 18
Total Common Equity		 -11 14 12 9.71 18
Common Stock		 1.89 46 66 83 118
Retained Earnings		 -13 -32 -54 -73 -100

Quarterly Balance Sheets for Nuvectis Pharma

This table presents Nuvectis Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 25 22 20 18 17 30 27 36 25
Total Current Assets		 25 22 20 18 17 30 27 36 25
Cash & Equivalents		 25 22 19 18 17 30 27 35 25
Other Current Assets		 0.34 0.20 0.25 0.18 0.14 0.28 0.21 0.15 0.27
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 25 22 20 18 17 30 27 36 25
Total Liabilities		 4.61 5.58 5.69 5.77 6.32 9.19 10 12 11
Total Current Liabilities		 4.61 5.58 5.69 5.77 6.32 9.19 10 12 11
Accounts Payable		 1.80 3.49 1.76 1.85 2.26 2.99 4.98 6.44 4.70
Accrued Expenses		 0.57 0.16 0.49 0.31 0.28 0.87 0.00 0.07 0.04
Current Employee Benefit Liabilities		 1.84 1.93 3.45 3.61 3.77 5.04 5.08 5.00 6.45
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 20 17 14 13 11 21 17 24 14
Total Preferred & Common Equity		 20 17 14 13 11 21 17 24 14
Total Common Equity		 20 17 14 13 11 21 17 24 14
Common Stock		 62 64 72 75 78 100 102 116 120
Retained Earnings		 -42 -48 -58 -63 -67 -79 -85 -92 -106

Annual Metrics And Ratios for Nuvectis Pharma

This table displays calculated financial ratios and metrics derived from Nuvectis Pharma's official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -48.06% -16.64% 10.84% -45.13%
EBIT Growth		 0.00% -48.06% -16.64% 10.84% -45.13%
NOPAT Growth		 0.00% -49.17% -19.04% 13.32% -38.93%
Net Income Growth		 0.00% -48.06% -16.64% 14.65% -39.17%
EPS Growth		 0.00% 50.00% 5.30% 22.38% -18.92%
Operating Cash Flow Growth		 0.00% -42.67% -17.66% 23.24% -30.72%
Free Cash Flow Firm Growth		 0.00% 0.00% -61.81% 19.35% -24.20%
Invested Capital Growth		 0.00% -283.91% -19.93% -27.36% -49.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -29.64% 2.41% 2.06% -4.42%
EBIT Q/Q Growth		 0.00% -29.64% 2.41% 2.06% -4.42%
NOPAT Q/Q Growth		 0.00% -30.66% -0.39% 2.06% -4.42%
Net Income Q/Q Growth		 0.00% -30.27% 0.33% 1.93% -4.20%
EPS Q/Q Growth		 0.00% 4.43% 5.30% 4.31% 3.65%
Operating Cash Flow Q/Q Growth		 0.00% -22.04% -2.14% 10.16% -10.41%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -7.34% 10.33% -12.63%
Invested Capital Q/Q Growth		 0.00% -76.79% -28.89% -42.76% -15.65%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 95.73% 95.89%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -304.15% -206.81% -168.51% -173.41% -188.03%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 790.02% -35.98% -168.51% -173.41% -188.03%
Return on Equity Simple (ROE_SIMPLE)		 117.10% -134.22% -182.44% -195.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.03 -13 -16 -14 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -67.30% -43.69% -31.86% -27.12% -28.47%
Return On Investment Capital (ROIC_SIMPLE)		 - - -131.37% -143.03% -104.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -19 -22 -20 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -19 -22 -20 -28
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 7.72 11.84 10.76 10.50
Price to Tangible Book Value (P/TBV)		 0.00 7.72 11.84 10.76 10.50
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.35 -1.39 -1.48 -1.72 -1.78
Leverage Ratio		 1.57 1.47 1.50 1.72 1.79
Compound Leverage Factor		 1.57 1.47 1.50 1.65 1.72
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 359.75% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -259.75% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.52 6.21 5.39 -1.35 2.15
Noncontrolling Interest Sharing Ratio		 359.75% 82.60% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 2.41 3.30 2.75 2.09 2.38
Quick Ratio		 2.37 3.23 2.74 2.08 2.38
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.19 -15 -12 -15
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -1.50 -5.77 -6.93 -8.82 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -4.27 -1.15 -1.90 -4.40
Enterprise Value (EV)		 26 90 125 86 162
Market Capitalization		 16 110 145 105 193
Book Value per Share		 ($2.58) $0.97 $0.70 $0.50 $0.72
Tangible Book Value per Share		 ($2.58) $0.97 $0.70 $0.50 $0.72
Total Capital		 4.24 14 12 9.71 18
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.74 -20 -19 -19 -32
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.33 -5.77 -6.93 -8.82 -13
Debt-free Net Working Capital (DFNWC)		 3.41 14 12 9.71 18
Net Working Capital (NWC)		 3.41 14 12 9.71 18
Net Nonoperating Expense (NNE)		 3.86 5.62 6.23 5.11 7.14
Net Nonoperating Obligations (NNO)		 -5.74 -20 -19 -19 -32
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.51) ($1.43) ($1.11) ($1.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 12.66M 15.56M 17.11M 21.81M
Adjusted Diluted Earnings per Share		 $0.00 ($1.51) ($1.43) ($1.11) ($1.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 12.66M 15.56M 17.11M 21.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.75M 17.77M 23.39M 26.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.03 -13 -16 -14 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.78% -2.01% -7.94%

Quarterly Metrics And Ratios for Nuvectis Pharma

This table displays calculated financial ratios and metrics derived from Nuvectis Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 17,231,337.00 17,326,594.00 17,768,824.00 18,356,060.00 18,652,688.00 - 23,391,499.00 23,634,586.00 25,456,848.00 - 26,491,702.00
DEI Adjusted Shares Outstanding		 17,231,337.00 17,326,594.00 17,768,824.00 18,356,060.00 18,652,688.00 - 23,391,499.00 23,634,586.00 25,456,848.00 - 26,491,702.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.34 -0.38 -0.23 -0.24 -0.22 - -0.23 -0.27 -0.39 - -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -4.78% -2.54% -3.01% 22.42% 29.21% 6.07% -27.84% -43.04% -78.80% -18.11% -13.47%
EBIT Growth		 -4.78% -2.54% -3.01% 22.42% 29.21% 6.07% -27.84% -43.04% -78.80% -18.11% -13.47%
NOPAT Growth		 -3.71% -1.30% -7.19% 19.56% 29.21% 6.07% -26.66% -42.04% -78.80% -18.11% -12.43%
Net Income Growth		 -0.07% 1.11% -3.01% 22.42% 29.38% 5.65% -27.84% -43.04% -79.68% -17.06% -13.47%
EPS Growth		 11.90% 16.33% 7.41% 31.58% 35.14% 12.20% -8.00% -15.38% -83.33% 13.89% 3.70%
Operating Cash Flow Growth		 26.67% -9.50% 8.77% 26.03% 25.89% 35.97% 4.22% -11.49% -86.94% -61.22% -55.99%
Free Cash Flow Firm Growth		 -147.43% -670.16% 54.21% -4.65% -1.94% 28.34% 48.19% 85.31% 91.02% 64.46% -454.47%
Invested Capital Growth		 -64.51% -19.93% -70.38% -30.93% -14.98% -27.36% -63.73% -77.54% -85.04% -49.90% -22.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.88% -11.50% 39.25% -6.16% 1.56% -55.29% 17.32% -13.76% -23.05% 2.27% 20.57%
EBIT Q/Q Growth		 -7.88% -11.50% 39.25% -6.16% 1.56% -55.29% 17.32% -13.76% -23.05% 2.27% 20.57%
NOPAT Q/Q Growth		 -6.69% -11.50% 35.97% -5.62% 6.12% -47.95% 13.66% -18.44% -18.18% 2.27% 17.82%
Net Income Q/Q Growth		 -3.03% -12.60% 37.01% -6.16% 6.21% -50.45% 14.66% -18.79% -17.81% 1.98% 17.28%
EPS Q/Q Growth		 2.63% -10.81% 39.02% -4.00% 7.69% -50.00% 25.00% -11.11% -46.67% 29.55% 16.13%
Operating Cash Flow Q/Q Growth		 20.55% -18.68% -13.19% 30.70% 20.40% -2.54% -69.33% 19.33% -33.47% 11.57% -63.84%
Free Cash Flow Firm Q/Q Growth		 -19.48% -65.87% 77.31% -132.77% -16.38% -16.61% 83.60% 34.01% 28.82% -361.30% -155.88%
Invested Capital Q/Q Growth		 -25.89% -28.89% 21.42% -2.68% -10.56% -42.76% -1.02% -11.35% -15.23% -15.65% 17.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.50% 96.45% 100.00% 100.00% 95.27% 96.88% 100.00% 100.00% 95.74% 96.02% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -120.53% -168.51% -170.23% -128.44% -140.00% -173.41% -115.28% -150.12% -145.00% -188.03% -154.43%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -120.53% -168.51% -170.23% -128.44% -140.00% -173.41% -115.28% -150.12% -145.00% -188.03% -154.43%
Return on Equity Simple (ROE_SIMPLE)		 -133.85% 0.00% -159.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.31 -4.81 -3.08 -3.25 -3.05 -4.51 -3.90 -4.62 -5.46 -5.33 -4.38
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.87% -9.28% -6.26% -5.52% -5.62% -9.21% -5.82% -7.65% -7.63% -7.90% -6.07%
Return On Investment Capital (ROIC_SIMPLE)		 - -39.39% -21.95% -25.94% -27.76% -46.48% -18.60% -27.36% -22.72% -28.96% -30.82%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.16 -6.87 -4.17 -4.43 -4.36 -6.45 -5.33 -6.33 -7.79 -7.62 -6.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.16 -6.87 -4.17 -4.43 -4.36 -6.45 -5.33 -6.33 -7.79 -7.62 -6.05
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 13.31 11.84 10.39 9.27 10.67 10.76 10.91 10.46 6.38 10.50 14.40
Price to Tangible Book Value (P/TBV)		 13.31 11.84 10.39 9.27 10.67 10.76 10.91 10.46 6.38 10.50 14.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.23 -1.48 -1.33 -1.30 -1.42 -1.72 -1.41 -1.53 -1.50 -1.78 -1.56
Leverage Ratio		 1.27 1.50 1.37 1.32 1.43 1.72 1.43 1.54 1.51 1.79 1.58
Compound Leverage Factor		 1.21 1.45 1.37 1.32 1.36 1.67 1.43 1.54 1.45 1.72 1.58
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 20.89 8.04 11.37 7.30 5.66 1.02 11.52 6.03 4.40 4.23 5.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.99 2.75 3.46 3.17 2.74 2.09 3.28 2.66 3.07 2.38 2.27
Quick Ratio		 3.96 2.74 3.42 3.14 2.72 2.08 3.25 2.64 3.06 2.38 2.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.20 -3.66 -0.83 -1.93 -2.25 -2.62 -0.43 -0.28 -0.20 -0.93 -2.38
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.37 -6.93 -5.44 -5.59 -6.18 -8.82 -8.91 -9.92 -11 -13 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.11 -1.15 -2.25 -1.32 -0.81 -1.90 -3.47 -4.33 -5.25 -4.40 -2.00
Enterprise Value (EV)		 200 125 126 98 100 86 199 150 118 162 180
Market Capitalization		 222 145 146 116 117 105 229 177 153 193 205
Book Value per Share		 $0.97 $0.70 $0.79 $0.68 $0.59 $0.50 $0.90 $0.71 $0.94 $0.72 $0.54
Tangible Book Value per Share		 $0.97 $0.70 $0.79 $0.68 $0.59 $0.50 $0.90 $0.71 $0.94 $0.72 $0.54
Total Capital		 17 12 14 13 11 9.71 21 17 24 18 14
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -22 -19 -19 -18 -17 -19 -30 -27 -35 -32 -25
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.37 -6.93 -5.44 -5.59 -6.18 -8.82 -8.91 -9.92 -11 -13 -11
Debt-free Net Working Capital (DFNWC)		 17 12 14 13 11 9.71 21 17 24 18 14
Net Working Capital (NWC)		 17 12 14 13 11 9.71 21 17 24 18 14
Net Nonoperating Expense (NNE)		 1.57 1.82 1.09 1.18 1.10 1.73 1.43 1.72 2.01 1.98 1.67
Net Nonoperating Obligations (NNO)		 -22 -19 -19 -18 -17 -19 -30 -27 -35 -32 -25
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.41) ($0.25) ($0.26) ($0.24) ($0.36) ($0.27) ($0.30) ($0.44) ($0.31) ($0.26)
Adjusted Weighted Average Basic Shares Outstanding		 16.10M 15.56M 16.56M 16.90M 17.23M 17.11M 19.94M 21.37M 22.72M 21.81M 23.41M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.41) ($0.25) ($0.26) ($0.24) ($0.36) ($0.27) ($0.30) ($0.44) ($0.31) ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding		 16.10M 15.56M 16.56M 16.90M 17.23M 17.11M 19.94M 21.37M 22.72M 21.81M 23.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 17.33M 17.77M 18.36M 18.65M 19.32M 23.39M 23.63M 25.46M 25.61M 26.49M 26.53M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.31 -4.81 -3.08 -3.25 -3.05 -4.51 -3.90 -4.62 -5.46 -5.33 -4.38
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.78% -1.46% -1.09% -1.25% -2.01% -7.55% -8.09% -8.44% -7.94% -2.97%

Financials Breakdown Chart

Key Financial Trends

Nuvectis Pharma (NASDAQ: NVCT) remains a pre-revenue biotech with meaningful cash on the balance sheet, but it is still burning through cash at a brisk pace. In Q1 2026, the company reported no revenue, a net loss of $6.1 million, and negative operating cash flow of $6.5 million. The good news is that NVCT ended the quarter with $25.1 million in cash and equivalents, which gives it some runway, though that runway is still being consumed quarter by quarter.

Top takeaways from the last several quarters:

  • Cash balance improved sequentially in Q1 2026. Cash and equivalents rose to $25.1 million from $18.1 million at Q2 2024 and $17.2 million at Q3 2024, helped by equity financing over time.
  • Operating assets and liabilities provided some offset to losses in multiple quarters. Working-capital changes helped reduce cash burn in most periods, including a $2.3 million benefit in Q1 2026 before the quarter still ended with a large cash outflow.
  • Interest and other income has added a modest cushion. NVCT reported other income of $210,000 in Q1 2026 and similar positive amounts in prior quarters, which slightly reduces pretax losses.
  • Share count growth has slowed recently. Weighted average basic shares were 23.4 million in Q1 2026, up from 21.8 million in Q4 2025 and 19.9 million in Q1 2025, but the pace of dilution appears less severe than earlier capital raises.
  • The company remains entirely R&D-driven. With no revenue across all periods shown, results will continue to depend on clinical progress and financing access rather than operating sales.
  • R&D spending has generally trended lower than some earlier periods. Q1 2026 R&D expense was $4.1 million versus $5.1 million in Q4 2025 and $5.8 million in Q3 2025, suggesting some moderation in spend.
  • SG&A also eased in Q1 2026. Selling, general and administrative expense fell to $2.15 million from $2.53 million in Q4 2025 and $2.02 million in Q3 2025, which may help contain cash burn if sustained.
  • Losses remain substantial and recurring. Net loss was $6.05 million in Q1 2026, after $7.31 million in Q4 2025 and $9.89 million attributable to common shareholders in Q3 2025.
  • Operating cash burn is still high. NVCT used $6.5 million in operating cash in Q1 2026, following $4.0 million in Q4 2025 and $4.5 million in Q3 2025.
  • Balance sheet equity has declined over time. Total common equity fell to $14.2 million in Q1 2026 from $24.0 million in Q3 2025 and $20.9 million in Q1 2025, reflecting continued accumulated losses.

Overall, NVCT is still in the classic biotech development-stage profile: no revenue, ongoing losses, and cash usage funded largely by periodic equity issuance. The company’s $25.1 million cash balance provides near-term support, but investors should watch the pace of operating cash burn and future financing needs closely.

07/06/26 07:34 PM ETAI Generated. May Contain Errors.

Nuvectis Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nuvectis Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Nuvectis Pharma's net income appears to be on an upward trend, with a most recent value of -$26.44 million in 2025, rising from -$12.89 million in 2021. The previous period was -$19 million in 2024. Find out what analysts predict for Nuvectis Pharma in the coming months.

Nuvectis Pharma's total operating income in 2025 was -$27.57 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $27.57 million

Over the last 4 years, Nuvectis Pharma's total revenue changed from $0.00 in 2021 to $0.00 in 2025, a change of 0.0%.

Nuvectis Pharma's total liabilities were at $13.30 million at the end of 2025, a 49.5% increase from 2024, and a 449.6% increase since 2021.

In the past 4 years, Nuvectis Pharma's cash and equivalents has ranged from $5.74 million in 2021 to $31.63 million in 2025, and is currently $31.63 million as of their latest financial filing in 2025.

Over the last 4 years, Nuvectis Pharma's book value per share changed from -2.58 in 2021 to 0.72 in 2025, a change of -127.9%.


Related Companies

Financial statements for NASDAQ:NVCT last updated on 6/25/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Three companies about to leapfrog Nvidia [And transform the entire industry]
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
Amazon, Google, Meta, and Microsoft just committed $700 billion
Amazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...
True Market Insiders | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel